RxDoctor Payments DataLook up a doctor →

Neetu Talreja, MD

Hospitalist · Detroit, MINPI 1326206889

Payments from drug & device makers

$6,399,480in general payments, 2019–2025

Across 1,481 payments — averaging $4321.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.2M
  • Sanofi US Services Inc.$849K
  • Amgen$763K
  • AstraZeneca$752K
  • Regeneron$611K
  • Novartis$461K
  • plus $1.8M from 33 others
$46,497in research payments, 2019–2025

Across 6 payments — averaging $7749.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$45K
  • Regeneron$2K

What the payments were for

  • Consulting fees$4,27327%
  • Speaking & faculty fees$4,50028%
  • Travel & lodging$7154%
  • Food & beverage$6,47040%
  • Education$610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,399,480 in reported general payments places this provider in the 95th percentile of 342 hospitalist providers in Michigan.

See all hospitalist providers in Michigan

Medicare billing

Part B allowed, 2024
$80,953
Medicare patients
164
Services billed
6,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab14$50,791
Breo ElliptaFluticasone/Vilanterol47$19,636
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,801
Epinephrine21$7,704
Advair HfaFluticasone Propion/Salmeterol11$4,778
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$4,263
SymbicortBudesonide/Formoterol Fumarate11$2,897
Arnuity ElliptaFluticasone Furoate11$2,245
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$1,828
Albuterol Sulfate HfaAlbuterol Sulfate55$1,336
Fluticasone Propionate91$1,187
Azelastine Hcl91$1,110
Ipratropium Bromide27$546
Omeprazole38$417
Montelukast Sodium46$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$210,422$34,68178 claims
Hikma Pharmaceuticals USAEpinephrine$16$7,70421 claims
AstraZenecaSymbicort$752,418$2,89711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 342 hospitalist providers in Michigan.

Other hospitalist in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →